San Francisco, California, September 21, 2017: The demand for gene therapy and antisense drug is rising at a very high pace in response to the increasing incidence of cancer witnessed worldwide. Besides this, high cholesterol and increasing incidence of Parkinson’s disease will pique the demand for gene therapy and antisense drug, as forecast by TMR Research in a report, titled “Gene Therapy and Antisense Drugs Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025.” The report is intended at providing a holistic overview of the global gene therapy and antisense drugs market. It covers various forces influencing the current business dynamics.
It covers the various growth drivers helping the market grow as well as the restraints posing threat. Furthermore, the report highlights various opportunities that will enable growth in the global gene therapy and antisense drugs market in the coming years. Considering the escalating number of patients diagnosed with cancer worldwide and the rising incidence of chronic ailments, novel therapeutics are introduced in the gene therapy and antisense drugs market.
Recently in June, 2017, a group of scientist from the University of Queensland has developed a novel technique capable of permanently treating allergies triggered by peanuts, shellfish, and venom. The treatment has already proven successful when tried on animals. Experts also foresee considerable potential in the technique as it could offer complete treatment for asthma as well. Such research and development activities intended to discover novel therapeutics are expected to give the market impetus in the coming years.
Despite witnessing positive scope for expansion, the market is reeling under difficulties in effectively delivering antisense technology to the brain. Furthermore, inevitable toxic side effects of the technology could create obstacles for the market as well. Nevertheless, attempts at developing new and more efficient antisense drugs will enable the market cope with dynamic business environment, thus confirming growth in the coming years.
For the purpose of the study, the report segments the global gene therapy and antisense drugs market based on various parameters. In terms of therapeutic area, the global gene therapy and antisense drugs market is segmented into cardiovascular diseases, anemia, cancer, cystic fibrosis, rheumatoid arthritis, mellitus and obesity, diabetes, and renal diseases. Based on gene transfer method, the market can be bifurcated into in vivo gene transfer and ex vivo gene transfer.
Regionally, the global gene therapy and antisense drugs market is segmented into Europe, North America, Asia Pacific, and Rest of the World. Among these regions, North America held dominance in the global market, trailed by Europe. The increasing incidence of cancer and other chronic ailments, besides unhealthy living practices is the key factor influencing the market’s growth in the region. In addition, the increasing research efforts to discover effective treatment for cancer will enable the market gain pace worldwide in the coming years.
Also during the course of the forecast period, Asia Pacific is forecast to exhibit strong growth. The increasing geriatric population and high population density are the key drivers of the gene therapy and antisense drugs market. Besides this, the rising demand for technologically advanced treatment and support from government aimed at boosting healthcare infrastructure will drive the gene therapy and antisense drugs market in Asia Pacific.
To gauge the prevailing competition, the report also profiles some of the leading companies operating in the global gene therapy and antisense drugs market. A few of these companies are Genome Therapeutics Corp., GenVec Inc., Isis Pharmaceuticals, Tekmira Pharmaceuticals Corporation, Avigen Inc., and Cell Genesys Inc., among others.
Click on the link below to request a sample copy of the report